NCT02151760 Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer Status COMPLETED Phase PHASE1
NCT02066961 A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer Status COMPLETED Phase N/A
NCT02051218 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02049190 Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Status UNKNOWN Phase PHASE1/PHASE2
NCT02036060 Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Status COMPLETED Phase PHASE2
NCT01981122 A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT01957436 A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT01933022 A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease Status TERMINATED Phase PHASE4
NCT01923727 Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT01815515 Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT01814150 The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel Status UNKNOWN Phase N/A
NCT01677897 Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients Status COMPLETED Phase PHASE2
NCT01560923 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Status COMPLETED Phase PHASE2
NCT01558219 Second-line Chemotherapy in Castration Resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT01303705 Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Status COMPLETED Phase PHASE1
NCT01153113 Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines Status WITHDRAWN Phase PHASE1/PHASE2
NCT01062503 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC Status COMPLETED Phase N/A
NCT01012141 Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer Status COMPLETED Phase PHASE2
NCT00942578 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Status COMPLETED Phase PHASE2